TY - JOUR AU - Y Chang, Joe PY - 2011 TI - Stereotactic ablative radiotherapy for stage I NSCLC: Successes and existing challenges JF - Journal of Thoracic Disease; Vol 3, No 3 (September 01, 2011): Journal of Thoracic Disease Y2 - 2011 KW - N2 - Stereotactic ablative radiotherapy (SABR) has emerged as a standard treatment of peripherally located medically inoperable stage I non-small cell lung cancer (NSCLC) (1-5). With SABR, local control of primary tumors is greater than 90% in tumors up to 5 cm, and regional lymph node recurrence within the chest is low (5% to 10%). Distant metastasis remains a dominant pattern of failure (10% to 20%). SABR has been accepted by the National Comprehensive Cancer Network (NCCN) and is included in the NCCN treatment guidelines, and SABR is widely used (>75%) by radiation oncology centers, including community hospitals, according to a recent survey by the American Society for Radiation Oncology (ASTRO) UR - https://jtd.amegroups.org/article/view/192